Peer support to improve HIV treatment adherence in high-risk populations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates a peer-delivered intervention called Peer Activate-LAI aimed at improving adherence to long-acting injectable PrEP/ART among Black, substance-using individuals living with or at high risk for HIV. The study compares the effectiveness of this intervention against enhanced treatment as usual over a 12-month period, focusing on adherence rates and substance use. It also assesses the implementation of the intervention, including its feasibility and acceptability, using mixed methods to understand the impact of structural racism and discrimination on adherence. The trial involves 186 participants and aims to address significant barriers to HIV treatment in marginalized communities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Able and willing to sign informed consent
* HIV status:

HIV negative with a negative HIV antibody/antigen test and meeting CDC(center for disease control and prevention) criteria for PrEP HIV positive with a positive antibody/antigen test

* Meeting indications for treatment based on Cabotegravir-LA (HIV negative) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV positive) prescribing information
* Moderate substance use, defined as a (World Health Organization Alcohol, Smoking and Substance Involvement Screening Test) WHO-ASSIST score of ≥4 for certain drugs (cocaine, amphetamines, inhalants, sedatives, hallucinogens, or opioids) or ≥11 for alcohol

Exclusion Criteria:

* Contraindications to Cabotegravir-LA (HIV-) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV+) use based on prescribing information or other medical/psychiatric conditions that may interfere with study participation
* Pregnant or breastfeeding

Where it's running

• HIPS (Harm reduction drop-in center)
  Washington D.C., District of Columbia, United States Recruiting
• Baltimore Safe Haven
  Baltimore, Maryland, United States Recruiting

Study contacts

• Study coordinator: Elana Rosenthal, MD
• Email: erosenthal@ihv.umaryland.edu
• Phone: 240-367-4157

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Motivational interviewing for male couples to reduce drug use and HIV risk

  This study is testing whether a special conversation technique for male couples can help reduce drug use and lower the risk of HIV.

  Recruiting Hunter College of City University of New York · Detroit, Michigan and 2 other locations · NCT06307977

• Peer support program to improve health for women living with HIV

  This study tests a program that combines therapy, exercise, and support from peers to help women living with HIV stick to their medications and improve their overall health.

  Recruiting University of California, San Diego · San Diego, California · NCT06216600

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.